Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211

Journal of Infectious Diseases

Volumn 196, Issue 2, 2007, Pages 304-312

  Gulick, Roy M ^a   Su, Zhaohui ^c   Flexner, Charles ^g   Hughes, Michael D ^c   Skolnik, Paul R ^d   Wilkin, Timothy J ^a   Gross, Robert ⁱ   Krambrink, Amy ^c   Coakley, Eoin ^j   Greaves, Wayne L ^l   Zolopa, Andrew ^k   Reichman, Richard ^b   Godfrey, Catherine ^h   Hirsch, Martin ^e   Kuritzkes, Daniel R ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j MONOGRAM BIOSCIENCES   (United States)

^k STANFORD UNIVERSITY   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ENFUVIRTIDE; MARAVIROC; PLACEBO; RITONAVIR; VICRIVIROC; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADD ON THERAPY; ADULT; ARTICLE; CANCER; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 34347379935     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518797     Document Type: Article

References (29)

1. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.org. 10 October 2006 update. Accessed 10 December 2006.
2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-43.
3. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100:10598-602.
4. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
5. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
6. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49:4911-9.
7. Schuermann D, Pechardscheck C, Rouzier R, et al. SCH 417690: antiviral activity of a potent new CCR5 receptor antagonist [abstract TuOa0205]. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Geneva: International AIDS Society, 2005:10-11.
8. Sansone A, Keung A, Tetteh E, et al. Pharmacokinetics of vicriviroc are not affected in combination with five different protease inhibitors boosted by ritonavir [abstract 582]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006:254.
9. Greaves W, Landovitz R, Fatkenheuer G, et al. Late virologic breakthrough in treatment-naive patients on a regimen of combivir + vicriviroc [abstract 161LB]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006:105..
10. Regulatory Compliance Center. Division of AIDS table for grading severity of adult adverse experiences. August 1992 and December 2004. Available at: http://rcc.tech-res-intl.com/tox_tables.htm. Accessed 20 December 2006.
11. Tremblay CL, Giguel F, Kollmann C, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46:1336-9.
12. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99:16249-54.
13. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8.
14. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV-1 chemokine coreceptor usage among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211. Clin Infect Dis 2007; 44:591-5.
15. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract THLB0215]. In: Program and abstracts of the XVI International AIDS Conference (Toronto). Geneva: International AIDS Society, 2006:27.
16. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997; 16: 100-3.
17. Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25:1462-5.
18. Burns JC, Shimizu C, Gonzalez E, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 2005; 192:344-9.
19. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38:1468-76.
20. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54:1157-61.
21. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758-61.
22. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203: 35-40.
23. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59:3561-4.
24. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy (part 1). Oncology 2002; 16:441-51.
25. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy (part 2). Oncology 2002; 16:657-65.
26. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000; 27:390-401.
27. Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev 2005; 4: CD003187.
28. Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results [abstract 104aLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:102.
29. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada [abstract 104bLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:103.